Executives On The Move: Operations Change At Khondrion And A Promotion At Grunenthal
Executive Summary
Khondrion BV, developer of therapies for mitochondrial disease, has appointed a former Novartis SVP as COO, and pain and inflammation medicines firm Grunenthal GmbH to promote acting CSO to CSO and director. Also, Royal DSM NV says CEO to resign in February.